Akeso Presents Updated Data on Cadonilimab Combination Therapy in PD-(L)1 Inhibitor-Resistant Advanced NSCLC at ELCC 2026

HONG KONG, April 6, 2026 /PRNewswire/ — Akeso, Inc. (9926.HK) (“Akeso” or the “Company”) announced that, at the 2026 European Lung Cancer Congress (ELCC 2026), it reported updated results with a median follow-up of 21.45 months from a prospective, open-label,…

More Stories

Teens Don‘t Worry About AI. Should They?

(NAPSI)—A new survey of U.S. teens by Junior Achievement USA (JA)—long a leader in experiential learning—and global research firm Ipsos shows that 73 percent believe AI (Artificial Intelligence) will have a mostly positive effect, or none at all, on their…

Read More »